ORAMED PHARMACEUTICALS INC.
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
ORMP$4.00+3.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| CURRENT ASSETS: | ||
| Cash and cash equivalents | $45,947 | $54,420 |
| Short-term deposits (note 2) | 10,979 | 55,281 |
| Marketable securities (note 3) | 5,417 | 3,441 |
| Investments at fair value (note 4,7) | 63,551 | 28,788 |
| Convertible note (note 9) | 4,636 | - |
| Prepaid expenses and other current assets | 2,741 | 1,291 |
| Total current assets | 133,271 | 143,221 |
| LONG-TERM ASSETS: | ||
| Long-term deposits | 2 | 2 |
| Marketable securities (note 3) | 8,371 | - |
| Investments at fair value (note 4,7) | 10,119 | 7,387 |
| Investment in associate at fair value (note 8) | 71,623 | - |
| Loan to an equity method investee (note 6) | 553 | - |
| Investment in real estate (note 5) | 1,921 | - |
| Other non-marketable equity securities (note 10) | 3,624 | 3,524 |
| Amounts funded in respect of employee rights upon retirement | 44 | 32 |
| Property and equipment, net | 586 | 698 |
| Operating lease right of use assets | 750 | 414 |
| Total long-term assets | 97,593 | 12,057 |
| Total assets | $230,864 | $155,278 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| CURRENT LIABILITIES: | ||
| Accounts payable and accrued expenses (note 11) | $6,201 | $5,140 |
| Payable to related parties (note 20) | 652 | 329 |
| Deferred income (note 8) | 1,353 | - |
| Dividend Payable | 10,595 | |
| Operating lease liabilities | 285 | 216 |
| Total current liabilities | 19,086 | 5,685 |
| LONG-TERM LIABILITIES: | ||
| Long-term deferred revenues (note 13) | 2,000 | 4,000 |
| Long-term deferred income (note 8) | 1,269 | - |
| Employee rights upon retirement | 39 | 30 |
| Operating lease liabilities | 540 | 156 |
| Dividend Payable | 275 | |
| Other liabilities | - | 60 |
| Deferred tax liabilities (note 18) | 7,911 | |
| Total long-term liabilities | 12,034 | 4,246 |
| COMMITMENTS (note 13) | ||
| EQUITY ATTRIBUTABLE TO COMPANY’S STOCKHOLDERS: | ||
| Common stock, $ 0.012 par value (60,000,000 authorized shares as of December 31, 2025 and December 31, 2024; 39,275,006 and 39,919,545 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively) | 472 | 480 |
| Additional paid-in capital | 322,708 | 322,401 |
| Accumulated deficit | (123,436) | (176,616) |
| Total stockholders’ equity | 199,744 | 146,265 |
| Non-controlling interests | - | (918) |
| Total equity | 199,744 | 145,347 |
| Total liabilities and equity | $230,864 | $155,278 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.